Table 2.

Properties of different co-delivery systems carrying similar cargo. Drug loading is provided as a weight percent, which is the mass of the drug loaded into the final formulation divided by the mass of the carrier material (i.e. polymer). In some cases where drug loading was not provided as a weight percent, the encapsulation efficiency, the percentage of the drug present during formulation that was actually encapsulated within the carrier, is used as an alternative measurement.

	Carrier	Specific Therapeutic	Approximate Size (nm)	Drug Loading	Ref
Drug/Gene
	Liposome	Paclitaxel and pEGFP-hTRAIL gene	74.8	2.2 wt%	16
	Polymeric Micelle	DOX and reporter gene	280	23.3 wt%	80
	Dendrimer	DOX and pORF-hTRAIL gene	200	33.3 wt%	14
	Linear Conjugate	PC-DOX and p53 gene	220–400	5 wt%	61
	Mesoporous Silica	Chloroquine and reporter gene	130	32 wt%	113
	DNA gel	DOX and p53 gene	145	1 wt%	17
Drug/siRNA
	Liposome	DOX and siRNA targeting MRP-1 and Bcl-2	100–140	70% encapsulation efficiency	34
	Polymeric Micelle	DOX and Bcl-2 siRNA	190	6.56 wt%	73
		DOX and P-gp siRNA	93–108	6 wt%	82
	Dendrimer	DOX and GAPDH siRNA	56	65% encapsulation efficiency	104
	Mesoporous Silica	DOX and P-gp siRNA	100–120	8.4 wt%	12
Drug/Drug hydrophobic/hydrophobic
	Polymeric Micelle	DOX and Wortmannin	< 100	22.9–26.7 wt% of each drug	72
	Dendrimer	DOX and 10-Hydroxycamptothecin	89	41.2 wt% DOX 19.2 wt% HCPT	111
	Linear Conjugate	DOX and Dexamethasone	8.5	8.4 wt% DOX 6.6 wt% Dex	59
hydrophobic/hydrophobic
	Polymeric Micelle	Paclitaxel and Gemcitabine hydrochloride	70	1.6 wt% Ptxl 1.6 wt% Gemcitabine	71
	Dendrimer	Paclitaxel and Alendronate	190	4.7 wt% Ptxl 11 wt% ALN	105
	Mesoporous Silica	DOX and Paclitaxel	50	24.2 wt% DOX 15.6 wt% Ptxl	116
	Janus Particle	DOX and Paclitaxel	305	0.6 wt% DOX 1.15 wt% Ptxl	125
	PLGA Nanoparticle	DOX and Paclitaxel	243	9.67 wt% total drug	10